Title : A phase 1 study of the MDM2 antagonist RO6839921, a pegylated prodrug of idasanutlin, in patients with advanced solid tumors.

Pub. Date : 2020 Aug

PMID : 31734832






2 Functional Relationships(s)
Download
Sentence
Compound Name
Protein Name
Organism
1 A phase 1 study of the MDM2 antagonist RO6839921, a pegylated prodrug of idasanutlin, in patients with advanced solid tumors. RG7388 MDM2 proto-oncogene Homo sapiens
2 RO6839921 is an inactive pegylated prodrug of idasanutlin, an MDM2 antagonist, developed for intravenous administration. RG7388 MDM2 proto-oncogene Homo sapiens